The following is a link to an interview with Dr Tian Zhang, a medical instructor in the Department of Medicine, Duke University School of Medicine, by OncLive at the 2016 Kidney Cancer Symposium, in which Dr Zhang discusses the challenges associated with vaccine development in kidney cancer and the hope that vaccines can still be the answer to improving the response rates with anti-PD-1/PD-L1 treatment in renal cell carcinoma (RCC).

Read more here